ZHISHAN WEIXIN BIOTECHNOLOGY
Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.
ZHISHAN WEIXIN BIOTECHNOLOGY
Industry:
Biotechnology Health Care Product Research
Founded:
2018-01-01
Address:
Chengdu, Sichuan, China
Country:
China
Status:
Active
Total Funding:
2 M CNY
Similar Organizations
Biosino Bio-Technology & Science
Biosino Bio-Technology & Science is engaged in research and development of invitro diagnostics reagent products.
BVG Life Sciences
BVG Life Sciences is a research and development lab for human, plant and animal products.
Delaware Center for Neuroscience Research
Delaware Center for Neuroscience Research creates infrastructure to support research and career development of neuroscientists in Delaware.
Joyo Pharma
Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.
Olympus Terumo Biomaterials
Olympus Terumo Biomaterials engages in the research and development relating to biomaterials and regenerative medicine.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
TaiwanJ Pharmaceuticals
TaiwanJ Pharmaceuticals into drug research and development and mainly for chronic inflammation related diseases.
Yidao Biotechnology
Yidao Biotechnology research and develops vaccines and biomedical products.
Investors List
Loyal Valley Capital
Loyal Valley Capital investment in Series A - Zhishan Weixin Biotechnology
Pan-Lin Capital
Pan-Lin Capital investment in Series A - Zhishan Weixin Biotechnology
SDIC Venture Capital
SDIC Venture Capital investment in Series A - Zhishan Weixin Biotechnology
Essence Capital
Essence Capital investment in Series A - Zhishan Weixin Biotechnology
Loyal Valley Capital
Loyal Valley Capital investment in Series A - Zhishan Weixin Biotechnology
Delian Capital
Delian Capital investment in Series A - Zhishan Weixin Biotechnology
Morningside Group
Morningside Group investment in Series A - Zhishan Weixin Biotechnology
Leimei Ruisi
Leimei Ruisi investment in Series A - Zhishan Weixin Biotechnology
Sichuan Talent Fund
Sichuan Talent Fund investment in Series A - Zhishan Weixin Biotechnology
Shanghai Junshi Biosciences
Shanghai Junshi Biosciences investment in Series A - Zhishan Weixin Biotechnology
More informations about "Zhishan Weixin Biotechnology"
Zhishan Weixin Biotechnology - Crunchbase
Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the …See details»
Zhishan Weixin Biotechnology - Funding, Financials, Valuation
Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases.See details»
Wuxi Zhishan Weixin Biotechnology Co., Ltd. - Drug pipelines, …
Last update 01 Nov 2024. Wuxi Zhishan Weixin Biotechnology Co., Ltd. Private Company |See details»
Zhishan Weixin Biotechnology - 2021-02-09 - Crunchbase
Feb 9, 2021 Organization Name . Zhishan Weixin Biotechnology . Announced Date Feb 9, 2021; Funding Type Series A; Funding Stage Early Stage Venture; Lead Investors. Edit Lead …See details»
Zhishan Weixin Biotechnology - Company Profile - Tracxn
Nov 7, 2024 The company is focusing on the development of drugs for rAAV gene therapy which includes in vivo gene therapy product for hemophilia B, ZS801. The company has product …See details»
Zhishan Weixin Biotechnology - Products, Competitors, Financials ...
Zhishan Weixin Biotechnology develops and researches biomedical drugs focused on gene therapy focusing on rAAV gene drug research and development and subversive production. It …See details»
Zhishan Weixin Biotechnology - Founders and Board of Directors
Zhishan Weixin Biotechnology founders & board of directors. Developer of gene therapies to treat genetic and neurodegenerative diseases. 2018 • Sichuan (China) • Series ASee details»
Zhishan Weixin Biotechnology funding & investors - Tracxn
Oct 31, 2024 Zhishan Weixin Biotechnology has raised funding over 1 round from 3 investors. Investors include Panlin Capital, SDIC Venture Capital Management and 1 other. Their latest …See details»
Zhishan Weixin - Products, Competitors, Financials, Employees ...
Zhishan Weixin engages in gene-drug development and technical services. The company was founded in 2018 and is based in Chengdu, China. You're one click away from the most …See details»
Zhishanweixin's gene therapy ZS802 for hemophilia A has ... - 資訊咖
Oct 20, 2023 Sichuan Zhishan Weixin Biotechnology Co., Ltd. was established in June 2018 and is located in Tianfu International Bio-city, Chengdu. It is a leading domestic gene therapy …See details»
China's first!"Made in Chengdu" gene therapy starts clinical …
Nov 21, 2024 Led by Dr. Dong Biao, a professor at the State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and a talented Rongpiao, Zhishan Weixin Bio is …See details»
Zhishan Weixin Biotechnology - Crunchbase
Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases.See details»
"Made in Chengdu" gene therapy starts clinical research!It will be ...
Nov 15, 2024 Dong Biao in Sichuan Zhishan Weixin Biotechnology Co., Ltd. is instructing employees to do experiments. On June 4, 2018, Zhishan Weixin was officially established. …See details»
Zhishan Weixin Biotechnology - CB Insights
Sep 2, 2021 See Zhishan Weixin Biotechnology funding rounds, investors, investments, exits and more. Evaluate their financials based on Zhishan Weixin Biotechnology's post-money …See details»
WCH starts the first clinical study of rAAV gene drugs for treating ...
ZS805 was developed by Prof. Dong Biao and Prof. Hoi Yee Chow of the State Key Laboratory of Biotherapy, and produced by Sichuan Zhishan Weixin Biotechnology Co., Ltd. and belongs to …See details»
Zhishan Weixin Biotechnology - 2023-02-01 - Crunchbase
Zhishan Weixin Biotechnology raised $296657 on 2023-02-01 in Series A. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log …See details»
Clinical trial of AVV therapy for hemophilia that promises a "one …
Jul 7, 2024 On August 30, the CDE official website showed that the clinical trial application of the AVV therapy product ZS801 injection independently developed by Sichuan Zhishan Weixin …See details»
ZS802 in Hemophilia A - Clinical Trials Registry - ICH GCP
Jul 25, 2022 Inclusion Criteria: Male ≥18 years and ≤65years of age; Confirmed diagnosis of hemophilia A, and endogenous FVIII ≤2%: <1% (<1 IU/dL) endogenous FVIII activity levels as …See details»
Sichuan Talent Fund - Investments, Portfolio & Company Exits
Feb 9, 2021 Sichuan Talent Fund has invested in Zhishan Weixin Biotechnology on Feb 9, 2021. How many investments has this organization made over time? Show . Which industries has …See details»